ONCY - オンコリティクス・バイオテック （Oncolytics Biotech Inc.）

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncoloytics Biotech Inc. (NASDAQ: ONCY ) reports that it is working toward an innovation in cancer immunotherapies with its leading drug candidate, pelareorep. The oncolytic virus may become a powerful cancer-fighting treatment in its own right while also enhancing the effectiveness of existing treatments. As the biotech company continues to pursue collaborations with major players in the oncology space, it’s aiming to fast-track approval and make its immunotherapy available to cancer patients around the world. Oncolytic Viruses Make Targeted Cancer Therapies Possible? Viruses enter and reproduce in certain types of cells due to the presence of specific receptors and other characteristics. Therefore, some viruses are naturally more tumor-selective than others. This means that certain viruses are able to infect and disrupt tumor cells but not healthy cells.

New York, USA, May 18, 2022 (GLOBE NEWSWIRE) -- Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials, Assesses DelveInsight Oncolytic Virus Cancer Therapy Pipeline involves 70+ key companies continuously working towards developing 100+ Oncolytic Virus Cancer therapies, as per DelveInsight DelveInsight''s '' Oncolytic Virus Cancer Therapy Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Oncolytic Virus Cancer Therapy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Oncolytic Virus Cancer Therapy pipeline domain. Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report DelveInsight''s Oncolytic Virus Cancer Therapy Pipeline report depicts a robust space with 70+ active players working to develop 100+ pipeline therapies for Oncolytic Viruses Cancer treatment. Leading Oncolytic Virus Cancer Therapy companies such as Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc.

PALM BEACH , Fla. , May 4, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years and will continue in the years to come. Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Human epidermal growth factor receptor 2-positive (HER2+) breast cancer constitutes approximately 20% of breast cancer cases and was historically associated with poor prognosis in the absence of effective treatments. The realization that introducing HER2-targeted therapies earlier into the disease management strategy could improve disease-free survival (DFS) has created a large market for HER2-directed therapies. Today, HER2+ breast cancer patients are living longer with their disease, thanks to established disease management strategies using regimens. According to Stats Market Research the HER2+ market is forecast to grow to $12.1B by 2030, at a Compound Annual Growth Rate (CAGR) of 1.5%.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncolytics Biotech Inc. (NASDAQ: ONCY ) focuses on developing more effective immunotherapies that can be adapted to a wide range of difficult-to-treat cancers like metastatic breast cancer, pancreatic cancer, and multiple myeloma. Using its proprietary immunotherapeutic agent, pelareorep, in combination with existing cancer treatments, the company’s goal is to renew hope in patients with more aggressive cancers who typically face a grim prognosis. In April, the company is expected to release new data from its glioblastoma study , in which it’s evaluating the potential of combining pelareorep with leading cancer therapies to improve the outlook for glioblastoma patients. Here’s a look at the glioblastoma market and how Oncolytics’ upcoming clinical results could break new ground in that space. Glioblastoma Market Glioblastoma multiforme (GBM) is one of the most common and aggressive malignant brain cancers and it typically develops in the brain or spinal cord.

Oncolytics Biotech press release (ONCY): Q4 GAAP EPS of -C$0.14.Net cash used in operating activities was C$22.4 million for the full year 2021, compared to C$22.1 million for the…

PALM BEACH , Fla. , May 4, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years and will continue in the years to come. Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Human epidermal growth factor receptor 2-positive (HER2+) breast cancer constitutes approximately 20% of breast cancer cases and was historically associated with poor prognosis in the absence of effective treatments. The realization that introducing HER2-targeted therapies earlier into the disease management strategy could improve disease-free survival (DFS) has created a large market for HER2-directed therapies. Today, HER2+ breast cancer patients are living longer with their disease, thanks to established disease management strategies using regimens. According to Stats Market Research the HER2+ market is forecast to grow to $12.1B by 2030, at a Compound Annual Growth Rate (CAGR) of 1.5%.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncolytics Biotech Inc. (NASDAQ: ONCY ) focuses on developing more effective immunotherapies that can be adapted to a wide range of difficult-to-treat cancers like metastatic breast cancer, pancreatic cancer, and multiple myeloma. Using its proprietary immunotherapeutic agent, pelareorep, in combination with existing cancer treatments, the company’s goal is to renew hope in patients with more aggressive cancers who typically face a grim prognosis. In April, the company is expected to release new data from its glioblastoma study , in which it’s evaluating the potential of combining pelareorep with leading cancer therapies to improve the outlook for glioblastoma patients. Here’s a look at the glioblastoma market and how Oncolytics’ upcoming clinical results could break new ground in that space. Glioblastoma Market Glioblastoma multiforme (GBM) is one of the most common and aggressive malignant brain cancers and it typically develops in the brain or spinal cord.

Oncolytics Biotech press release (ONCY): Q4 GAAP EPS of -C$0.14.Net cash used in operating activities was C$22.4 million for the full year 2021, compared to C$22.1 million for the…

Randomized phase 2 metastatic breast cancer trial (BRACELET-1) on track for top-line data in Q4 2022 Clinical breast cancer data indicate pelareorep-induced changes in blood T cell populations may be a predictive biomarker – a key finding for de-risking a phase 3 registrational breast…

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncolytics Biotech Inc. (NASDAQ: ONCY ) in January announced its partner in China — Adlai Nortye — has advanced the second dose level in a bridging clinical trial evaluating Oncolytics’ pelareorep in combination with paclitaxel therapy as a treatment for metastatic breast cancer. The news came after determination that the first dose level administered beginning in October showed no safety issues, and Oncolytics continues to complete parallel clinical trials of the same treatment in North America in collaboration with Pfizer Inc. (NYSE: PFE ) and Merck KGaA (OTCMKTS: MKKGY). The bridging trial will allow Adlai Nortye to include data from the North American metastatic breast cancer trials of the same combination treatment in future submissions to the National Medical Products Administration (NMPA), China’s regulatory equivalent of the Food and Drug Administration (FDA).

Oncolytics Biotech (NASDAQ:ONCY) will be releasing its earnings data before the market opens on Friday, November 5th. Analysts expect Oncolytics Biotech to post earnings of ($0.15) per share for the quarter. Persons interested in registering for the companys earnings conference call can do so using this link. Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results []

Oncolytics Biotech (NASDAQ:ONCY) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The []